The founders and management team are biotechnology industry veterans with decades of drug development experience
Mark de Souza, Ph.D.
Mark is an entrepreneur in the rare disease and dermatology space. He is a co-founder and CEO of Chromaderm (topical PKC-beta inhibitor for melasma) and Executive Chairman of Wings Therapeutics and NFlection Therapeutics. He was previously the Executive Chairman of PellePharm (topical hedgehog inhibitor for Gorlin Syndrome), founding CEO of Lotus Tissue Repair (intravenous collagen VII for dystrophic epidermolysis bullosa, now being developed by Phoenix Tissue Repair), and VP of Business Development at Dyax Corp (kallikrein inhibitors for hereditary angioedema). He is an advisor to the CureGM1 Foundation and the Special Needs Aquatic Program.
James W. Fordyce
Jim is an entrepreneur in the rare disease and dermatology space, following 25+ years as an investor in multiple biotechnology companies including Genentech, Centocor, Regeneron, Applied Biosystems, and Dyax (kallikrein inhibitors for hereditary angioedema). He was the founding managing partner of Prince Ventures. He is a co-founder and CFO of Chromaderm (topical PKC-beta inhibitor for melasma). He was previously the founding CFO of Lotus Tissue Repair (intravenous collagen VII for dystrophic epidermolysis bullosa, now being developed by Phoenix Tissue Repair). He is Chairman Emeritus of the Lasker Foundation.
Erkki Ruoslahti, M.D., Ph.D.
Erkki is a Distinguished Professor and former president of Sanford-Burnham Prebys Medical Discovery Institute and a founder of the Center for Nanomedicine at UCSB. He is a pioneer in the field of cell and extracellular matrix biology and discoverer of fibronectin, the RGD cell attachment motif, RGD-binding integrins, and decorin. He is a member of the U.S. National Academy of Sciences and the National Academy of Medicine. On the entrepreneurial side, he is an inventor of about 150 patents and a fellow of the National Academy of Inventors. He has founded several biotech companies, including Telios, Inc. and DrugCendR, Inc.
Jean Tang, M.D., Ph.D.
Jean is a Professor of Dermatology at the Stanford University Medical Center. Her research focuses on genetic skin diseases such as Epidermolysis Bullosa (EB) and Basal Cell Nevus Syndrome (BCNS). Jean is a co-founder of PellePharm (topical hedgehog inhibitor for BCNS). She conducted clinical trials with gene therapy for Dystrophic EB at Stanford, which was licensed to Abeona Therapeutics.
Hal Landy, M.D.
Hal is a board-certified Pediatric Endocrinologist with 30 years of clinical research experience in academics and industry. He has held VP positions at Serono, Genzyme & Repligen with numerous successful drug approvals in growth, wasting and lysosomal disorders. He was most recently consulting Chief Medical Officer of Valerion Therapeutics. Previously he was CMO and VP, Medical Affairs at Enobia Pharma prior to its acquisition by Alexion Pharma. Subsequently, Hal served as a medical advisor to Lotus Tissue Repair. He currently consults for several biotech companies and venture funds and is consulting Chief Medical Officer of Valerion Therapeutics.
Deborah has 30 years of experience in the design and implementation of development strategies for therapeutic drugs and biotechnology products. Over the course of her career, she has been responsible for the strategic design and operational oversight of more than 70 drug candidates in several therapeutic areas, including rare diseases and dermatology. She was most recently the CEO of Valerion Therapeutics. She previously served as VP of Regulatory Affairs and Clinical Operations at Enobia Pharma prior to its acquisition by Alexion Pharma, and Regulatory Advisor to Lotus Tissue Repair. She currently consults for several biotech companies and is consulting CEO of Wings Therapeutics.
Franke Riske, Ph.D.
Frank is Managing Director of the BioTechnology Process Group at BDO. He has over 30 years of experience developing and overseeing manufacturing processes for protein drugs. Prior to joining BioProcess Technology Consultants, which was acquired by BDO, Frank served in multiple CMC positions at Genzyme, Epic Therapeutics, Repligen, and Hoffmann-La Roche.
Frederick Reno, Ph.D.
Fred established a toxicology consulting practice 25 years ago after 20 years with Hazleton Laboratories (now Covance). While with Hazleton, he started as a study director and eventually rose to the position of Vice President over all toxicology operations in Virginia, Maryland and Wisconsin. All of his consulting activities are with biotechnology and pharmaceutical companies and involve the development of small molecule and biologic drugs in various stages of development.